January 2, 2019 10:23 AM EST

Boyu Capital helps point Celgene-partnered Antengene down a quick path to commercialization

Amber Tong

Shanghai-based Antengene has ushered in the first biotech mega-round of the year, designed to fuel a quick commercial turnaround of in-licensed cancer drugs.

The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boyu Capital helps point Celgene-partnered Antengene down a quick path to commercialization

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Secretive Treeline Biosciences discloses $421M financing in filing

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

BenevolentAI CEO is out after less than a year on the job

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Boyu Cap­i­tal helps point Cel­gene-part­nered An­ten­gene down a quick path to com­mer­cial­iza­tion

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Boyu Capital helps point Celgene-partnered Antengene down a quick path to commercialization